In fact, TP53 and C-MYC have been postulated as key targets of NSD2 in MM, and their altered expressions are directly related with aggressiveness and a poorer outcome in different subsets of myeloma patients (including both NSD2-related myeloma patients and NSD2 non-related ones) [96,97]. Here, MYC is linked to plasma cell myeloma.